Some foods and drinks can actually cause bladder irritation or exacerbate symptoms. According to Dr. Anika Ackerman, a ...

The firms launched the global Phase II bladder cancer trial for autogene cevumeran after seeing early success in pancreatic ...

New data suggest that, in recent years, US cancer incidence has generally remained stable, and the rate of cancer deaths has generally decreased.

The Pancreatic Cancer Action Network Fellowship, funded by the Francois Wallace Monahan Fund, is designed to help advance developing pancreatic cancer research. This Fellowship is available to a ...

From 2018 to 2022, cancer death rates decreased an average of 1.7% per year for men and an average of 1.3% per year for women ...

Clinical results offered at the recent meeting of the American Urological Association in Las Vegas signal that better treatments may lie ahead for non-muscle invasive bladder cancer. BioWorld Clinical ...

The PoC 2 phase will provide a concentrated focus on interventional cancer pain management applications like pancreatic, gall bladder, liver, and bile duct, with potential further expansion in ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer trial ... Hepatitis and pancreatitis were the most common grade 3 or ...

TAR-200 demonstrated high DFS and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer with papillary-only disease. The phase 2b SunRISe-1 study showed over 80% ...

From 2000 to 2021, the incidence of pancreatic adenocarcinoma rose among all age groups in the United States, with the highest increase in those aged 15-34 years. During the same period ...

US pharma major Pfizer (NYSE: PFE) reported new Phase III data over the weekend showing that its investigational PD-1 inhibitor sasanlimab, delivered subcutaneously, significantly improved outcomes ...